Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Noxxon Pharma NV (ALNOX) EUR1

Sell:€0.45 Buy:€0.47 Change: €0.0215 (4.77%)
Market closed |  Prices as at close on 5 March 2021 | Switch to live prices |
Sell:€0.45
Buy:€0.47
Change: €0.0215 (4.77%)
Market closed |  Prices as at close on 5 March 2021 | Switch to live prices |
Sell:€0.45
Buy:€0.47
Change: €0.0215 (4.77%)
Market closed |  Prices as at close on 5 March 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

NOXXON Pharma NV is a biotechnology company based in the Netherlands that focuses on cancer treatments. The Company's main product is the Spiegelmer platform. Spiegelmers are a variant of a drug class called aptamers, which are based on deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) and are built on a backbone of mirror-image RNA or DNA - L-stereoisomers. The Company's lead candidate, NOX-A12, is under development as a combination therapy for a number of cancer indications using immuno-oncology approaches, such as immune checkpoint inhibition and current standards of care, such as chemotherapy and radiotherapy. The Company also develops NOX-E36, which is aimed at the treatment of complications arising from diabetic nephropathy.

Contact details

Address:
Max-Dohrn-Str. 8-10
BERLIN
10589
Germany
Telephone:
+49 (30) 7262470
Website:
https://www.noxxon.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ALNOX
ISIN:
NL0012044762
Market cap:
€28.70 million
Shares in issue:
39.85 million
Sector:
Biotechnology
Exchange:
Euronext Paris
Country:
Netherlands
Currency:
Euro
Indices:
n/a

Key personnel

  • Maurizio PetitBon
    Chairman of the Supervisory Board
  • Aram Mangasarian
    Chief Executive Officer, Member of the Management Board
  • Matthias Baumann
    Chief Medical Officer, Member of the Management Board
  • Jarl Jungnelius
    Chief Medical Officer, Member of the Management Board
  • Sven Klussmann
    Chief Scientific Officer, Member of the Management Board

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.